A Phase I Study of Oral Melphalan Combined With LBH589 for Patients With Relapsed or Refractory Multiple Myeloma (MM)

Trial Profile

A Phase I Study of Oral Melphalan Combined With LBH589 for Patients With Relapsed or Refractory Multiple Myeloma (MM)

Completed
Phase of Trial: Phase I/II

Latest Information Update: 27 Feb 2015

At a glance

  • Drugs Panobinostat (Primary) ; Melphalan
  • Indications Multiple myeloma
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Biomira USA
  • Most Recent Events

    • 24 Apr 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 07 Jun 2011 Trial design and progress published in conjunction with the 47th Annual Meeting of the American Society of Clinical Oncology. To date, 25 patients have been enrolled.
    • 31 Jul 2009 Planned number of patients changed from 36 to 40 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top